Equities

Inotiv Inc

Inotiv Inc

Actions
  • Price (EUR)2.76
  • Today's Change0.08 / 2.99%
  • Shares traded3.00k
  • 1 Year change+69.33%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 08:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

  • Revenue in USD (TTM)501.06m
  • Net income in USD-99.22m
  • Incorporated1975
  • Employees1.96k
  • Location
    Inotiv Inc2701 Kent AveWEST LAFAYETTE 47906-1350United StatesUSA
  • Phone+1 (317) 463-4527
  • Fax+1 (765) 497-1102
  • Websitehttps://www.inotivco.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.